Low, M. D. v. Omni Life Science, Inc.

CourtDistrict Court, N.D. Illinois
DecidedOctober 11, 2022
Docket1:21-cv-01568
StatusUnknown

This text of Low, M. D. v. Omni Life Science, Inc. (Low, M. D. v. Omni Life Science, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Low, M. D. v. Omni Life Science, Inc., (N.D. Ill. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION

WARREN G. LOW, M.D. and ) THOMAS K. TKACH, M.D., ) ) Plaintiffs, ) ) No. 21 C 1568 v. ) ) Magistrate Judge Finnegan OMNI LIFE SCIENCE, INC. and ) GEORGE CIPOLLETTI, ) Underlying Litigation: ) United States District Court for the Defendants. ) Western District of Oklahoma, ) Case No. 5:18-CV-305-SLP

ORDER Non-Party Andrew McLeod filed this matter seeking to quash a Rule 45 deposition subpoena issued to him by Plaintiffs Warren G. Low, M.D., and Thomas K. Tkach, M.D., in a case they filed against Defendants Omni Life Science, Inc. (“OMNI”) and George Cipolletti in the Western District of Oklahoma. The district judge referred the motion to this Court to conduct necessary proceedings and enter an Order or Report and Recommendation as appropriate. (Doc. 7). On April 7, 2021, this Court granted the unopposed motion, noting that “Plaintiffs [had] communicated to non-party McLeod by email that ‘No one will be appearing on behalf of Plaintiffs in the Northern District of Illinois.’” (Doc. 11). McLeod has now filed an opposed motion for sanctions, arguing that in issuing the subpoena, Plaintiffs failed to take reasonable steps to avoid imposing an undue burden on him. (Doc. 13). As a sanction, he seeks payment of $24,522.40 in attorney’s fees that he says were incurred in this matter, plus additional fees to be determined (likely in a similar amount) for drafting and filing the motion for sanctions. For reasons stated here, the motion for sanctions is denied. BACKGROUND Plaintiffs filed the underlying Oklahoma lawsuit on April 5, 2018, alleging that Defendants breached a product development and surgical consulting services agreement

executed by Plaintiffs and OMNI in 2006 and 2007. That case (No. 5:18-CV-305-SLP) remains pending in the Western District of Oklahoma, with Allen M. Gardner of Latham & Watkins LLP (among others) representing Defendants. A. The Subpoena to McLeod In January 2019, McLeod joined Corin Group, an international orthopedic company, as President of Corin USA, and in March 2019, Corin Group acquired OMNI. Though this acquisition took place nearly a year after Plaintiffs filed their lawsuit, Defendant OMNI introduced McLeod’s name into the case on August 19, 2020 when it served Second Supplemental Responses to Plaintiffs’ First Set of Interrogatories and

Requests for Production (“Supplemental Discovery Responses”). (No. 18-cv-305-SLP, Doc. 102-9). In response to Interrogatory No. 2, seeking the identity of all persons “who purport to have knowledge or relevant information concerning the facts or circumstances of this case,” OMNI provided a list of individuals that ended with “Andy McLeod.” (Id. at 4).1 In response to Interrogatory No. 23, OMNI identified Andy McLeod and provided his

1 Interrogatory 2 also said the “answer should include all persons who heard or claim to have heard any statements made by any party or witness concerning any aspect of the claims, defenses, or incidents alleged and all persons with knowledge of any kind concerning any claims, defenses, or incidents alleged.” (No. 18-CV-305-SLP, Doc. 102-9, at 20-21). Plaintiffs attached a partial (undated) version of the discovery responses to their Objections to the sanctions motion. (Doc. 21-1). email address with Coring Group as one used “to communicate with Plaintiffs.” (Id. at 21).2 On December 8, 2020, Plaintiffs asked Defendants to provide dates for the deposition of McLeod. (Doc. 2-1, at 32). Defendants responded less than two hours later, questioning what relevant information McLeod, a high-level Corin executive, could

possess. (Id. at 32-33). On December 15, 2020, Plaintiffs explained that McLeod had conversations “with the doctors [Plaintiffs Low and Tkach] about this [litigation],” and the following day pointed out that OMNI had identified McLeod’s email as one used to communicate with Plaintiffs. (Id.). Defendants remained unconvinced that McLeod was a proper deponent, and over the following weeks the parties exchanged correspondence and engaged in meet and confer conferences in an effort to resolve the dispute. (Id. at 32-33, 36-38; Doc. 24-1, at 2). These efforts proved unsuccessful and on March 2, 2021, Plaintiffs issued a notice to take McLeod’s deposition (on March 23, 2021 by Zoom Video Communication or similar videoconferencing platform). The notice stated that the

subpoena (which was attached) would be served on McLeod. (Doc. 2-1, at 47). Several days later on March 11, 2021, Plaintiffs served that deposition subpoena, seeking to depose McLeod via Zoom on March 23, 2021. (Id. at 49). It does not appear that the parties had further any discussions on the issue until March 22, 2021 when Plaintiffs

2 More specifically, Interrogatory No. 23 requested OMNI to “Identify any and all email accounts used by you for communications relating to royalties paid to medical service providers.” Subject to a number of objections, OMNI provided certain emails and then noted: “In March 2019, Corin Group acquired Omni. Following that time, communications relating to Plaintiffs using the following email address” but none was provided. The answer then concluded: “Specific email addresses used to communicate with Plaintiffs are” and provided the email address for Andy McLeod at Coring Group. (Doc. 21-1, at 3). received by email a copy of the motion to quash the subpoena that had been filed that day. B. The Illinois Lawsuit Defendants’ attorneys from Latham & Watkins are representing McLeod in responding to the subpoena. Since McLeod resides in Chicago, Illinois, counsel filed a

motion to quash the subpoena on McLeod’s behalf in the Northern District of Illinois. Accompanying that motion was a declaration from McLeod dated March 22, 2021 stating that: he has “no unique or firsthand knowledge of any of the events alleged in, or related to, the Amended Complaint”; he “had no involvement whatsoever in any events relevant to the claims or defenses in the dispute”; and “if I were to be deposed, I would not be able to testify concerning any unique information relevant to the dispute. My testimony would consist only of second-hand information that other individuals – mostly counsel – have told me about the underlying dispute.” (Doc. 2-1, McLeod Decl., at 29-30). McLeod acknowledged speaking with Plaintiffs about the pending lawsuit on two occasions, and

provided his recollection of those discussions. Notably, his summary made clear that neither he nor the Plaintiffs said anything relevant to the claims, defenses, and damages in the lawsuit.3

3 The declaration states in this regard:

Since joining Corin USA in January 2019, I have only met Plaintiffs twice-first at the American Association of Hip and Knee Surgeons conference in November 2019, and again in January 2020. During these brief interactions, any reference to the pending lawsuit was very limited. I mentioned that I was aware of the lawsuit and received briefings from counsel regarding the lawsuit’s progress, but that I was not actively involved in or managing the litigation. I recall stating that I was hopeful that a settlement could be reached, but other than this single comment, we did not discuss any facts relating to the dispute or anything else relevant or related to the lawsuit. Rather, our discussions focused on the potential future relationship between Plaintiffs and Corin USA. After the case was referred (Doc. 7), this Court held a telephone status on March 30, 2021. Plaintiffs’ counsel did not appear even though McLeod’s counsel had emailed them the pertinent documents and advised them of the court date. (Doc. 9; Doc. 10 ¶ 5; Doc. 10-2, at 5).4 The Court set a briefing schedule on the motion to quash and instructed McLeod to submit a status report by April 6, 2021 addressing certain questions. (Doc. 9).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Alberts v. HCA INC.
405 B.R. 498 (District of Columbia, 2009)
Stormans Inc v. Mary Selecky
738 F.3d 1178 (Ninth Circuit, 2013)
Scherer v. GE Capital Corp.
185 F.R.D. 351 (D. Kansas, 1999)
Wells Fargo Bank, N.A. v. Konover
259 F.R.D. 206 (D. Connecticut, 2009)
Noble Roman's, Inc. v. Hattenhauer Distributing Co.
314 F.R.D. 304 (S.D. Indiana, 2016)
Balfour Beatty Infrastructure, Inc. v. PB & A, Inc.
319 F.R.D. 277 (N.D. California, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
Low, M. D. v. Omni Life Science, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/low-m-d-v-omni-life-science-inc-ilnd-2022.